MX2020005405A - Derivados de piridinona y su uso como inhibidores selectivos de alk-2. - Google Patents

Derivados de piridinona y su uso como inhibidores selectivos de alk-2.

Info

Publication number
MX2020005405A
MX2020005405A MX2020005405A MX2020005405A MX2020005405A MX 2020005405 A MX2020005405 A MX 2020005405A MX 2020005405 A MX2020005405 A MX 2020005405A MX 2020005405 A MX2020005405 A MX 2020005405A MX 2020005405 A MX2020005405 A MX 2020005405A
Authority
MX
Mexico
Prior art keywords
inhibitors
pyridinone derivatives
selective alk
alk
selective
Prior art date
Application number
MX2020005405A
Other languages
English (en)
Inventor
Thomas Ullrich
Sylvie Chamoin
Mika Lindvall
Luca Arista
Dimitrios Lizos
Nikolaus Johannes Stiefl
Sven Weiler
Pier Luca D''ALESSANDRO
Sylvie Teixeira-Fouchard
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2020005405A publication Critical patent/MX2020005405A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La invención se refiere a un compuesto de Fórmula I o una de sus sales farmacéuticamente aceptables, un método para la fabricación de los compuestos de la invención, y sus usos terapéuticos. La presente invención además proporciona una combinación de agentes farmacológicamente activos y una composición farmacéutica.
MX2020005405A 2017-11-24 2017-11-24 Derivados de piridinona y su uso como inhibidores selectivos de alk-2. MX2020005405A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2017/057389 WO2019102256A1 (en) 2017-11-24 2017-11-24 Pyridinone derivatives and their use as selective alk-2 inhibitors

Publications (1)

Publication Number Publication Date
MX2020005405A true MX2020005405A (es) 2020-08-13

Family

ID=60702886

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005405A MX2020005405A (es) 2017-11-24 2017-11-24 Derivados de piridinona y su uso como inhibidores selectivos de alk-2.

Country Status (24)

Country Link
US (1) US11160797B2 (es)
EP (1) EP3713927B1 (es)
JP (1) JP7091455B2 (es)
KR (1) KR20200091422A (es)
CN (1) CN111433195B (es)
AU (1) AU2017440306B2 (es)
BR (1) BR112020010171A2 (es)
CA (1) CA3081651A1 (es)
CL (1) CL2020001277A1 (es)
CO (1) CO2020005885A2 (es)
CR (1) CR20200211A (es)
CU (1) CU20200035A7 (es)
DO (1) DOP2020000088A (es)
EA (1) EA202091293A1 (es)
EC (1) ECSP20026023A (es)
ES (1) ES2908252T3 (es)
IL (1) IL274722A (es)
JO (1) JOP20200127A1 (es)
MX (1) MX2020005405A (es)
PE (1) PE20201282A1 (es)
PH (1) PH12020550763A1 (es)
RU (1) RU2020120538A (es)
SG (1) SG11202003920QA (es)
WO (1) WO2019102256A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7504880B2 (ja) 2018-10-26 2024-06-24 ケロス セラピューティクス インコーポレイテッド Ａｌｋ２阻害剤の結晶形
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
CN113354631B (zh) * 2021-06-01 2022-11-18 江苏大学 一种1,3,4-噁二唑衍生物及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR950704485A (ko) 1992-11-17 1995-11-20 로이드 제이. 오울드·에드워드 에이, 맥더모 2세 액티빈 리셉터-유사 키나제, 세린 트레오닌 키나제 도메인을 갖는 단백질 및 이들의 용도(activin receptor-like kinases, proteins having serine threonine kinase domains and their use)
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA2649770C (en) 2006-04-18 2017-08-15 The Trustees Of The University Of Pennsylvania Mutated acvr1 for diagnosis and treatment of fibrodysplasia ossificans progressiva (fop)
MX2009002418A (es) 2006-09-05 2009-04-23 Medarex Inc Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
WO2008033408A2 (en) 2006-09-12 2008-03-20 The General Hospital Corporation Methods for identifying compounds that modulate cell signaling and methods employing such compounds
JP5638961B2 (ja) 2008-03-13 2014-12-10 ザ ジェネラル ホスピタル コーポレイション Ｂｍｐシグナル伝達経路のインヒビター
KR101862327B1 (ko) * 2010-05-07 2018-05-29 질레드 코네티컷 인코포레이티드 피리돈 및 아자-피리돈 화합물 및 사용 방법
PH12013500294A1 (en) 2010-08-20 2017-08-23 Wyeth Llc Designer osteogenic proteins
JP2014504286A (ja) 2010-12-06 2014-02-20 ピラマル エンタープライジーズ リミテッド 置換イミダゾキノリン誘導体
HUE053994T2 (hu) 2012-03-01 2021-08-30 Array Biopharma Inc Szerin/treonin kináz inhibitorok
WO2015148654A1 (en) * 2014-03-26 2015-10-01 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting bmp
US20170305883A1 (en) * 2014-10-01 2017-10-26 The Brigham And Women's Hospital, Inc. Compositions and Methods for Inhibiting BMP
CN107531697A (zh) * 2015-04-16 2018-01-02 默克专利股份公司 3‑(1h‑苯并咪唑‑2‑基)‑1h‑吡啶‑2‑酮衍生物

Also Published As

Publication number Publication date
BR112020010171A2 (pt) 2020-11-03
CN111433195B (zh) 2023-04-25
CR20200211A (es) 2020-06-19
EA202091293A1 (ru) 2020-11-23
ES2908252T3 (es) 2022-04-28
PH12020550763A1 (en) 2021-04-26
CU20200035A7 (es) 2021-03-11
CN111433195A (zh) 2020-07-17
ECSP20026023A (es) 2020-07-31
JP2021512850A (ja) 2021-05-20
RU2020120538A (ru) 2021-12-24
WO2019102256A1 (en) 2019-05-31
CL2020001277A1 (es) 2020-11-13
CA3081651A1 (en) 2019-05-31
EP3713927A1 (en) 2020-09-30
US11160797B2 (en) 2021-11-02
AU2017440306A1 (en) 2020-05-21
CO2020005885A2 (es) 2020-07-31
JP7091455B2 (ja) 2022-06-27
DOP2020000088A (es) 2020-08-31
KR20200091422A (ko) 2020-07-30
US20200360357A1 (en) 2020-11-19
EP3713927B1 (en) 2021-12-15
JOP20200127A1 (ar) 2020-05-21
IL274722A (en) 2020-07-30
RU2020120538A3 (es) 2021-12-24
PE20201282A1 (es) 2020-11-24
SG11202003920QA (en) 2020-06-29
AU2017440306B2 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
PH12016500756A1 (en) Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
MX2020011652A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
MX2015008975A (es) Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn).
MY196427A (en) Piperidinyl Indole Derivatives And Their Use As Complement Factor B Inhibitors
PH12016502539A1 (en) Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
MX2017012295A (es) Derivados formilados n-heterociclicos como inhibidores de fgfr4.
PH12019500328A1 (en) Aza-indazole compounds for use in tendon and/or ligament injuries
PH12020550763A1 (en) Pyridinone derivatives and their use as selective alk-2 inhibitors
NZ763311A (en) Benzimidazole derivatives and their uses
PH12019500849A1 (en) Naphthyridinone derivatives and their use inthe treatment of arrhythmia
MX2016014946A (es) Derivados de carboxamida.
HK1254636A1 (zh) 作为可溶性鸟苷酸环化酶激活剂的茚满衍生物及其用途
PH12019500327A1 (en) Indazole compounds for use in tendon and/or ligament injuries
PH12016502247A1 (en) Carboxamide derivatives